The Life Sciences Industry Insights
The Life Sciences Industry Insights Newsletter
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on PharmaXcelerate as their must-read source for the latest news, analysis and data on drugs and the companies that make them.
Every business day, PharmaXcelerate and its family of publications covers the waterfront in the pharma business, from late-stage drug development through the entire lifecycle. Learn about regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulations, M&A and beyond.
A distinctive element of our summits is the active participation of local pharmaceutical authorities and regulatory agencies, offering insight into national priorities, evolving standards, and regional market dynamics.
Life Sciences
The Future of Sterile Fill-Finish: How Advanced Manufacturing Is Redefining Injectable Production
The future of sterile fill-finish is becoming faster, smarter and more automated. Jubilant Pharmova’s latest FDA-cleared isolator-based manufacturing line in Spokane highlights how advanced technology is helping the industry expand injectable production while strengthening sterility assurance, flexibility and quality.
Roche and Eli Lilly Advance Alzheimer’s Diagnosis With FDA-Cleared pTau217 Blood Test
A simple blood test could change how Alzheimer’s disease is detected and assessed. Roche and Eli Lilly’s newly FDA-cleared pTau217 test brings blood-based biomarker testing one step closer to routine clinical care, potentially making Alzheimer’s assessment more accessible, scalable and less invasive.
Replimune wins FDA approval for Tudriqev in advanced melanoma after two previous rejections
Commercial Readiness Starts Earlier Than You Think: Why Manufacturing Strategy Can Make or Break a Product Launch
Blueprints for the Future: How AI Is Transforming Pharmaceutical Facility Design
Sustainability vs. Sterility: Can Single-Use Technologies Become Greener?
Annex 1 One Year Later: What Pharmaceutical Manufacturers Have Learned
Validation 4.0: Why Pharmaceutical Validation Is Moving Beyond Documentation
AI in GxP Manufacturing: How to Validate AI Without Breaking Compliance
FDA Pauses "Radical Transparency" Initiative After Industry Pushback Over Drug Rejection Letters
"How much transparency is too much when it comes to protecting innovation?"
FDA Expands Sunscreen Options for the First Time in 20 Years
Hemophilia in Focus: A Wake-Up Call for Pharma Innovation
Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
AstraZeneca Expands Breztri’s Reach With FDA Approval for Asthma
